CD147 and Prostate Cancer: A Systematic Review and Meta-Analysis.
BACKGROUND
Prostate cancer is one of the most common non-cutaneous malignancies in men. We aimed to systemically evaluate the relationship between the expression of CD147 in tissues and the clinicopathological features of prostate cancer.


RESULTS
PubMed (1966-2016), EMBASE (1980-2016), the Cochrane Library (1996-2016), Web of Science (1945-2016), China National Knowledge Infrastructure (1982-2016), and the WanFang databases (1988-2016) were searched. Literature quality assessment was performed with the Newcastle-Ottawa Scale. Meta-analysis was performed by using Review Manager 5.3 and Stata 13.0. A total of 12591 prostate cancer patients from 14 studies were included. The results of the meta-analysis showed that there were significant differences in the positive expression rate in the following comparisons: prostatic cancer tissues vs. normal prostate tissues (odds ratio [OR] = 26.93, 95% confidence interval [CI] 7.95-91.20, P < 0.00001), prostatic cancer tissues vs. benign prostatic hyperplasia tissues (OR = 20.54, 95% CI 8.20-51.44, P < 0.00001), high Gleason score vs. low Gleason score (OR = 2.39, 95% CI 1.33-4.27, P = 0.03), TNM III to IV vs. TNM I to II (OR = 9.95, 95% CI 4.96-19.96, P < 0.00001), low or moderate differentiation vs. high differentiation (OR = 8.12, 95% CI 3.69-17.85, P < 0.00001), lymph node metastasis vs. non-lymph node metastasis (OR = 4.31, 95% CI 1.11-16.71, P = 0.03), and distant metastasis vs. non-distant metastasis (OR = 8.90, 95% CI 3.24-24.42, P < 0.00001).


CONCLUSIONS
The CD147 positive expression rate was closely related to the clinical characteristics of prostate cancer, but more research is needed to confirm the findings owing to the results of the subgroups.
People's Hospital of Hunan Province, Chang Sha, Hu Nan Province, China.
Fei
F
Peng
Reproductive Department, Xiangya Hospital, Central South University, Changsha, China.
Hui
H
Li
People's Hospital of Hunan Province, Chang Sha, Hu Nan Province, China.
Zhaoze
Z
Ning
Urology of Xiangya Hospital, Central South University, Changsha, China.
Zhenyu
Z
Yang
Xiangya Medical School, Central South University, Changsha, China.
Hongru
H
Li
Reproductive Department, Xiangya Hospital, Central South University, Changsha, China.
Yonggang
Y
Wang
People's Hospital of Hunan Province, Chang Sha, Hu Nan Province, China.
Fang
F
Chen
People's Hospital of Hunan Province, Chang Sha, Hu Nan Province, China.
Yi
http://orcid.org/0000-0002-2515-8942
Y
Wu
PLoS One. 2016 Jan 25;11(1):e0147191
26807740
World J Urol. 2013 Apr;31(2):305-11
22903772
N Engl J Med. 2003 Jun 19;348(25):2491-9
12815134
Tumour Biol. 2014 Nov;35(11):11647-53
25139103
BMC Cancer. 2014 Sep 06;14:655
25193387
Eur Urol. 2011 Jan;59(1):120-7
20980095
BJU Int. 2016 Nov;118(5):763-769
27009882
Lancet Oncol. 2014 Jun;15(7):700-12
24831977
J Urol. 2015 Aug;194(2):392
26195362
Oncotarget. 2016 Feb 23;7(8):9429-47
26882566
Cancer Res. 2015 Jan 1;75(1):171-80
25403912
Cancer Immunol Immunother. 2008 Sep;57(9):1367-79
18273614
Am J Transl Res. 2015 Feb 15;7(2):356-63
25901202
Am J Pathol. 2005 Jan;166(1):209-19
15632013
Oncol Rep. 2015 Jul;34(1):67-76
25998266
Pathol Oncol Res. 2009 Sep;15(3):369-74
19048397
Eur J Pharmacol. 2013 Jan 5;698(1-3):429-34
23146660
BMC Cancer. 2015 Jul 25;15:549
26209327
Andrologia. 2008 Apr;40(2):130-3
18336465
BMC Cancer. 2011 Jul 25;11:312
21787388
Exp Mol Pathol. 2013 Oct;95(2):227-34
23948277
Biometrics. 2000 Jun;56(2):455-63
10877304
Oncol Lett. 2016 Feb;11(2):1375-1381
26893746
Chin J Cancer. 2013 Jun;32(6):342-52
23114087
Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1047-54
24636974
Pathologe. 2016 Feb;37(1):17-26
26809207
Am J Pathol. 2013 Feb;182(2):577-85
23178078
Lancet. 2001 Sep 22;358(9286):966-70
11583750
PLoS One. 2014 Jun 30;9(6):e101027
24979746
Urol J. 2014 Sep 06;11(4):1788-92
25194077
Int J Cancer. 2012 Jan 15;130(2):300-8
21328337
Eur Urol. 2012 Jun;61(6):1079-92
22424666
Genet Mol Res. 2015 Jun 18;14(2):6844-51
26125892
Clin Invest Med. 2011 Dec 01;34(6):E358
22129926